-Reuters
Needham Maintains Buy on Vaxcyte, Raises Price Target to $58
Needham analyst Joseph Stringer maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price target from $52 to $58.
Related Posts
Maxeon Solar Technologies Introduces New U.S. Commercial Partner Program
Maxeon Solar Technologies, Ltd. (NASDAQ:MAXN), a global leader in solar innovation and channels, has introduced its new Commercial Partner Program empowering U.S. solar installers and dealers to boost their sales
Why Couchbase Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Mobiquity Technologies, Inc. (NASDAQ: MOBQ) shares gained 124% to $0.3325. Mobiquity Technologies launched ElecAlytics, an AI-Powered analytics suite added to its ElecTech platform for political campaigns.
UNITY Biotechnology Announces 24-Week Data From Phase 2 BEHOLD Study Of UBX1325 In Patients With Diabetic Macular Edema
A single injection of UBX1325 led to a statistically significant and clinically relevant improvement in Best Corrected Visual Acuity (BCVA) of 7.6 ETDRS letters at 24 weeks compared to sham treatment
UBX1325